Evidence map›Paper›PMID 31037585›Full record

ArticleStem cell reviews and reports2019

Effects of VEGF

Birol Vural, Gokhan Duruksu, Fisun Vural, Merve Gorguc, Erdal Karaoz

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04444245 (Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04444245 phase1unknown statusnot on this mapstarted 2022, after this paper: background citation

Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection

TypeinterventionalSponsorBlack Tie Medical, Inc.Ran2022 to 2025Enrolled100ConditionsOvarian Failure, Perimenopausal Disorder, Hormone DisturbanceArmslipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Birol VuralSchool of Medicine, Department of Obstetrics and Gynecology, Reproductive Endocrinology and Infertility and Assisted Reproductive Technology (ART), Kocaeli University, Unit. Izmit, 41380, Kocaeli, Turkey. vuralbirol@yahoo.com.tr.
Gokhan DuruksuGraduate School of Health Sciences, Department of Stem Cell, Center for Stem Cells and Gene Therapies Research and Practice, Kocaeli University, Izmit, 41380, Kocaeli, Turkey.
Fisun VuralDepartment of Obstetrics and Gynecology, University of Health Sciences- Haydarpasa Numune Training and Research Hospital, 34668, Istanbul, Turkey.
Merve GorgucGraduate School of Health Sciences, Department of Stem Cell, Center for Stem Cells and Gene Therapies Research and Practice, Kocaeli University, Izmit, 41380, Kocaeli, Turkey.
Erdal KaraozDepartment of Histology and Embryology, Istinye University, 34460, Istanbul, Turkey.
Kocaeli Üniversitesi · TRHaydarpaşa Numune Eğitim ve Araştırma Hastanesi · TRIstinye University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Premature ovarian insufficiency (POI), a fertility disorder affecting women under 40 years of age, is characterized by early loss of ovarian function. This study was aimed to maintain ovarian function in POI animal models by mesenchymal stem cells (MSCs) transplantation with/without the supplementation of platelet-rich plasma (PRP). Adipose tissue-derived MSCs were isolated from inbred rats (Fisher-344), and constitutive expression of both VEGF and GFP were maintained by transfection with plasmids, pVEGF and pGFP-N. PRP was derived from the blood of healthy untreated rats. A total of 60 rats were divided into 5 groups of 12 rats in each. First group was kept as untreated-control (Control), and POI model was induced in Fisher-344 rats by cyclophosphamide in the next four groups. Second group was kept as sham-operated-control (Sham). MSC, PRP and MSC+ PRP-treated groups were transplanted following the validation of POI model in rats. After 2 months following the transplantation, anti-mullerian-hormone (AMH) and oestradiol (E

Indexed as

Mesenchymal Stem Cell TransplantationPlatelet-Rich PlasmaAllograftsAnimalsCyclophosphamideDisease Models, AnimalFemaleHumansMesenchymal Stem CellsOvaryPrimary Ovarian InsufficiencyRatsRats, Inbred F344Vascular Endothelial Growth Factor ACyclophosphamideVascular Endothelial Growth Factor Avascular endothelial growth factor A, ratCyclophosphamideGranulosa cellsMesenchymal stem cellsOocytePlatelet-rich plasmaPremature ovarian insufficiencyTheca cellsVascular endothelial growth factor

Identifiers

PMID31037585
OpenAlexW2942901183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.